Free Trial
→ BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you? (From Awesomely, LLC) (Ad)tc pixel Free AAPG Stock Alerts

Ascentage Pharma Group International (AAPG) Financials

Ascentage Pharma Group International logo
$21.57 -0.33 (-1.51%)
Closing price 03:59 PM Eastern
Extended Trading
$21.79 +0.22 (+1.02%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Ascentage Pharma Group International

Annual Income Statements for Ascentage Pharma Group International

This table shows Ascentage Pharma Group International's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -130 -111 -35 -131
Consolidated Net Income / (Loss)		 -128 -130 -56 -178
Net Income / (Loss) Continuing Operations		 -130 -111 -35 -131
Total Pre-Tax Income 		-131 -112 -34 -131
Total Operating Income		 -131 -98 -25 -123
Total Gross Profit		 27 27 130 75
Total Revenue		 0.00 31 134 82
Operating Revenue		 - 31 134 82
Total Cost of Revenue		 0.00 4.30 3.98 7.00
Operating Cost of Revenue		 - 4.30 3.98 7.00
Total Operating Expenses		 131 125 155 198
Selling, General & Admin Expense		 23 26 26 35
Research & Development Expense		 108 100 130 163
Total Other Income / (Expense), net		 -0.51 -14 -8.83 -7.73
Interest Expense		 - 14 8.83 7.73
Income Tax Expense		 -0.62 -1.01 1.43 0.99
Basic Earnings per Share		 ($0.49) ($0.46) ($0.18) ($0.07)
Diluted Earnings per Share		 ($0.49) ($0.46) ($0.18) ($0.07)

Quarterly Income Statements for Ascentage Pharma Group International

No quarterly income statements for Ascentage Pharma Group International are available.

Annual Cash Flow Statements for Ascentage Pharma Group International

This table details how cash moves in and out of Ascentage Pharma Group International's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -61 -5.28 -18 41
Net Cash From Operating Activities		 -95 1.58 4.18 -0.76
Net Cash From Continuing Operating Activities		 -109 1.58 4.18 -0.76
Net Income / (Loss) Continuing Operations		 -129 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 8.83 2.53 2.87 2.98
Changes in Operating Assets and Liabilities, net		 3.41 -0.95 1.31 -3.75
Net Cash From Investing Activities		 -56 -6.49 -3.33 -3.94
Net Cash From Continuing Investing Activities		 -37 -6.49 -3.33 -3.94
Purchase of Property, Plant & Equipment		 -34 -6.49 -3.33 -3.94
Net Cash From Financing Activities		 90 -0.36 -19 45
Net Cash From Continuing Financing Activities		 90 -0.36 -19 45
Repayment of Debt		 -17 -135 -92 -132
Issuance of Debt		 111 134 73 177
Other Financing Activities, net		 0.00 0.00 0.00 0.00
Cash Interest Paid		 - 13 8.30 7.34

Quarterly Cash Flow Statements for Ascentage Pharma Group International

No quarterly cash flow statements for Ascentage Pharma Group International are available.

Annual Balance Sheets for Ascentage Pharma Group International

This table presents Ascentage Pharma Group International's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 352 359 567
Total Current Assets		 177 185 393
Cash & Equivalents		 154 173 353
Accounts Receivable		 21 11 36
Inventories, net		 2.28 0.90 4.09
Plant, Property, & Equipment, net		 128 116 112
Total Noncurrent Assets		 48 57 62
Goodwill		 3.48 3.38 3.53
Intangible Assets		 12 10 9.43
Noncurrent Deferred & Refundable Income Taxes		 8.43 6.06 4.57
Other Noncurrent Operating Assets		 24 37 44
Total Liabilities & Shareholders' Equity		 361 395 756
Total Liabilities		 342 321 376
Total Current Liabilities		 298 282 343
Short-Term Debt		 253 229 283
Accounts Payable		 10 13 15
Accrued Expenses		 29 35 40
Other Current Liabilities		 5.41 5.14 5.36
Total Noncurrent Liabilities		 45 39 33
Noncurrent Deferred Revenue		 5.12 3.77 0.93
Noncurrent Deferred & Payable Income Tax Liabilities		 1.49 0.74 0.00
Other Noncurrent Operating Liabilities		 38 35 32
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 18 74 380
Total Preferred & Common Equity		 17 72 379
Total Common Equity		 17 72 379
Common Stock		 0.03 0.03 0.04
Treasury Stock		 -3.01 -0.00 -0.42
Accumulated Other Comprehensive Income / (Loss)		 -756 -791 -1,003
Other Equity Adjustments		 776 863 1,382
Noncontrolling Interest		 1.44 1.37 1.39

Quarterly Balance Sheets for Ascentage Pharma Group International

No quarterly balance sheets for Ascentage Pharma Group International are available.

Annual Metrics And Ratios for Ascentage Pharma Group International

This table displays calculated financial ratios and metrics derived from Ascentage Pharma Group International's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - 0.00
DEI Adjusted Shares Outstanding		 - - - 0.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - 0.00
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% -38.89%
EBITDA Growth		 0.00% -7.16% 24.16% -390.22%
EBIT Growth		 0.00% -1.47% 24.16% -390.22%
NOPAT Growth		 0.00% 2.66% 58.19% -390.22%
Net Income Growth		 0.00% -1.85% 57.37% -219.81%
EPS Growth		 0.00% 4.88% 0.00% 61.06%
Operating Cash Flow Growth		 0.00% 102.09% 111.14% -118.23%
Free Cash Flow Firm Growth		 0.00% 0.00% 88.99% -5,294.12%
Invested Capital Growth		 0.00% 0.00% -14.18% 29.25%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 97.03% 91.48%
EBITDA Margin		 0.00% 0.00% -75.08% -149.54%
Operating Margin		 0.00% 0.00% -39.55% -149.54%
EBIT Margin		 0.00% 0.00% -75.08% -149.54%
Profit (Net Income) Margin		 0.00% 0.00% -41.37% -216.50%
Tax Burden Percent		 97.67% 98.03% 55.10% 136.20%
Interest Burden Percent		 100.00% 100.00% 100.00% 106.30%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -36.80% -80.31%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -70.24% -3.78%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -83.74% 2.00%
Return on Equity (ROE)		 0.00% -706.39% -120.54% -78.31%
Cash Return on Invested Capital (CROIC)		 0.00% -363.56% -21.53% -105.83%
Operating Return on Assets (OROA)		 0.00% 0.00% -28.38% -26.53%
Return on Assets (ROA)		 0.00% 0.00% -15.64% -38.41%
Return on Common Equity (ROCE)		 0.00% -651.32% -116.88% -77.84%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -766.10% -76.78% 0.00%
Net Operating Profit after Tax (NOPAT)		 -91 -89 -37 -86
NOPAT Margin		 0.00% 0.00% -27.69% -104.68%
Net Nonoperating Expense Percent (NNEP)		 0.00% 91.70% 33.44% -76.53%
Return On Investment Capital (ROIC_SIMPLE)		 - -32.79% -12.30% -12.96%
Cost of Revenue to Revenue		 0.00% 0.00% 2.97% 8.52%
SG&A Expenses to Revenue		 0.00% 0.00% 19.99% 42.90%
R&D to Revenue		 0.00% 0.00% 96.59% 198.12%
Operating Expenses to Revenue		 0.00% 0.00% 136.59% 241.02%
Earnings before Interest and Taxes (EBIT)		 -131 -133 -101 -123
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -124 -133 -101 -123
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 7.42 1.75 0.51
Price to Tangible Book Value (P/TBV)		 0.00 83.89 2.16 0.53
Price to Revenue (P/Rev)		 0.00 0.00 0.94 2.34
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 2.08 1.97 1.02
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 1.37 1.50
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 114.54 43.93 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 13.70 3.10 0.74
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 4.89 1.19 -0.53
Leverage Ratio		 0.00 19.08 7.71 2.04
Compound Leverage Factor		 0.00 19.08 7.71 2.17
Debt to Total Capital		 0.00% 93.20% 75.61% 42.68%
Short-Term Debt to Total Capital		 0.00% 93.20% 75.61% 42.68%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.53% 0.45% 0.21%
Common Equity to Total Capital		 0.00% 6.27% 23.94% 57.11%
Debt to EBITDA		 0.00 -1.90 -2.27 -2.31
Net Debt to EBITDA		 0.00 -0.74 -0.55 0.57
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -2.84 -6.15 -3.29
Net Debt to NOPAT		 0.00 -1.11 -1.50 0.82
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -1.44 -0.64 -0.16
Noncontrolling Interest Sharing Ratio		 0.00% 7.79% 3.04% 0.61%
Liquidity Ratios		 - - - -
Current Ratio		 0.00 0.59 0.66 1.15
Quick Ratio		 0.00 0.59 0.65 1.13
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -198 -22 -113
Operating Cash Flow to CapEx		 -278.72% 30.47% 125.55% -19.32%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -14.65
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -0.10
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -0.61
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.38 0.18
Accounts Receivable Turnover		 0.00 0.00 8.41 3.45
Inventory Turnover		 0.00 0.00 2.51 2.80
Fixed Asset Turnover		 0.00 0.00 1.10 0.72
Accounts Payable Turnover		 0.00 0.00 0.35 0.50
Days Sales Outstanding (DSO)		 0.00 0.00 43.39 105.72
Days Inventory Outstanding (DIO)		 0.00 0.00 145.69 130.29
Days Payable Outstanding (DPO)		 0.00 0.00 1,044.40 726.63
Cash Conversion Cycle (CCC)		 0.00 0.00 -855.33 -490.61
Capital & Investment Metrics		 - - - -
Invested Capital		 0.00 109 93 121
Invested Capital Turnover		 0.00 0.00 1.33 0.77
Increase / (Decrease) in Invested Capital		 0.00 109 -15 27
Enterprise Value (EV)		 0.00 227 184 123
Market Capitalization		 126 126 126 192
Book Value per Share		 $0.00 $2.32 $0.21 $51.71
Tangible Book Value per Share		 $0.00 $0.21 $0.17 $49.94
Total Capital		 0.00 271 302 663
Total Debt		 0.00 253 229 283
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 0.00 99 56 -70
Capital Expenditures (CapEx)		 34 6.49 3.33 3.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -22 -41 -20
Debt-free Net Working Capital (DFNWC)		 0.00 132 132 333
Net Working Capital (NWC)		 0.00 -121 -97 50
Net Nonoperating Expense (NNE)		 37 41 18 92
Net Nonoperating Obligations (NNO)		 0.00 90 20 -260
Total Depreciation and Amortization (D&A)		 6.96 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -30.37% -24.27%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 98.24% 405.97%
Net Working Capital to Revenue		 0.00% 0.00% -71.90% 61.14%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.07)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 348.27M 0.00
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 348.27M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 348.27M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -91 -89 -37 -86
Normalized NOPAT Margin		 0.00% 0.00% -27.69% -104.68%
Pre Tax Income Margin		 0.00% 0.00% -75.08% -158.96%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -15.88
NOPAT to Interest Expense		 0.00 0.00 0.00 -11.11
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -16.39
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -11.62
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3.03% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Ascentage Pharma Group International

No quarterly metrics and ratios for Ascentage Pharma Group International are available.


Financials Breakdown Chart

Frequently Asked Questions About Ascentage Pharma Group International's Financials

When does Ascentage Pharma Group International's fiscal year end?

According to the most recent income statement we have on file, Ascentage Pharma Group International's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Ascentage Pharma Group International's net income changed over the last 3 years?

Ascentage Pharma Group International's net income appears to be on an upward trend, with a most recent value of -$177.74 million in 2025, rising from -$128.01 million in 2022. The previous period was -$55.58 million in 2024. View Ascentage Pharma Group International's forecast to see where analysts expect Ascentage Pharma Group International to go next.

What is Ascentage Pharma Group International's operating income?
Ascentage Pharma Group International's total operating income in 2025 was -$122.77 million, based on the following breakdown:
  • Total Gross Profit: $75.10 million
  • Total Operating Expenses: $197.87 million
How has Ascentage Pharma Group International's revenue changed over the last 3 years?

Over the last 3 years, Ascentage Pharma Group International's total revenue changed from $0.00 in 2022 to $82.10 million in 2025, a change of 8,209,806,800.0%.

How much debt does Ascentage Pharma Group International have?

Ascentage Pharma Group International's total liabilities were at $375.99 million at the end of 2025, a 17.1% increase from 2024, and a 9.9% increase since 2023.

How much cash does Ascentage Pharma Group International have?

In the past 2 years, Ascentage Pharma Group International's cash and equivalents has ranged from $154.06 million in 2023 to $353.22 million in 2025, and is currently $353.22 million as of their latest financial filing in 2025.

How has Ascentage Pharma Group International's book value per share changed over the last 3 years?

Over the last 3 years, Ascentage Pharma Group International's book value per share changed from 0.00 in 2022 to 51.71 in 2025, a change of 5,171.2%.


Related Companies

Financial statements for NASDAQ:AAPG last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel